Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS)) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy, safety, tolerability, pharmacokinetic characteristics, and immunogenicity of plonmarlimab in subjects with hemophagocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Plonmarlimab (Plonmarlimab)

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Hemophagocytic Lymphohistiocytoses | Phase 2 | Status: COMPLETED